Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of WT1 peptide vaccine DSP-7888 in childhood, adolescent and young adult soft tissue sarcoma
jRCT1091220276Phase 2Completed
- Start
- Feb 2017
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of adegramotide + nelatimotide in soft tissue sarcoma (STS), rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) (2 arms). Primary endpoint: Event-free survival. Started Feb 2017; status: completed.
02
Drugs
adegramotide + nelatimotide
03
Conditions
soft tissue sarcoma (STS)rhabdomyosarcoma (RMS)non-rhabdomyosarcoma soft tissue sarcoma (NRSTS)
Beyond the preview
Go deeper on jRCT1091220276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220276.